Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

NCT07207811 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07207811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07207811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Recruiting
Start date
October 2, 2025
Completion date
June 29, 2029
Enrollment
1,280 (estimated)
Sites
297

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin amyloid cardiomyopathy (attr cm)